Fulgent Genetics, Inc., together with its affiliated companies, offers a comprehensive suite of COVID-19, molecular diagnostic, and genetic testing services to healthcare providers and individuals globally. Their diverse array of genetic tests covers a wide range of applications, including extensive oncology panels and solid tumor molecular profiling for cancer identification, Beacon carrier screening for inherited conditions, and specialized rapid whole genome testing for critically ill infants in NICU and PICU units. Other offerings include a newborn genetic analysis panel, a front-line test…
| Price | $21.57 |
|---|---|
| Market cap | $612.55M |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |
| Exchange | NASDAQ |
| 52-week range | 13.46-31.04 |
| Beta | 0.93 |
Explore FLGT's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.